(SeaPRwire) – AI platform honored for real-world clinical influence via analysis of raw 12-lead ECG data, facilitating earlier identification of multiple cardiovascular conditions
NEW ORLEANS, March 29, 2026 — Medical AI, a firm focused on AI-powered electrocardiogram (ECG) solutions for detecting and monitoring cardiovascular disease, today revealed it has won the first-ever Global Digital Health Award at the American College of Cardiology’s (ACC) Annual Scientific Session. The award was presented by Dr. Ami Bhatt, ACC’s Chief Innovation Officer, during the conference’s Future Hub Theater session, which spotlights cutting-edge technologies shaping the future of cardiovascular care.
Medical AI was chosen for its AI platform that examines raw data from standard 12-lead electrocardiograms, allowing clinicians to detect multiple cardiovascular conditions—including heart failure, myocardial infarction, and aortic stenosis—sooner and with greater accuracy. The award recognizes non-U.S. organizations demonstrating measurable real-world impact through digital health innovations like artificial intelligence, data analytics, and connected health technologies that advance cardiovascular care.
“Receiving the first Global Digital Health Award from the American College of Cardiology is an immense honor,” said Joon-myoung Kwon, Chief Executive Officer of Medical AI. “Our goal has always been to turn AI advances into practical tools that help clinicians detect cardiovascular disease earlier and manage patients more effectively. This recognition highlights the growing importance of AI-driven diagnostics in improving patient outcomes worldwide.”
“ACC supports emerging technologies that further our mission to transform cardiovascular care and enhance heart health for all,” Dr. Bhatt stated. “Medical AI’s groundbreaking AI work to improve the cardiovascular field and patients’ lives is exactly the impactful solution we aimed to recognize with the Global Digital Health Award. Congratulations to Medical AI on this achievement.”
Medical AI’s technology analyzes raw waveform data from standard 12-lead ECGs to enable earlier detection and monitoring of a broad range of cardiovascular conditions, helping clinicians identify disease sooner in routine care settings. The company’s solutions have shown strong real-world clinical adoption, now deployed in 250 hospitals and health screening centers globally. Following national reimbursement approval in 2023, the technology is currently used to evaluate approximately 220,000 patients per month on a reimbursed basis. The company’s technology platform is backed by an expanding body of clinical research, including over 70 publications in SCI-indexed journals, with findings presented as Late-Breaking Research at the 2025 European Society of Cardiology Heart Failure Congress. Medical AI has earned regulatory approvals in six countries, including CE marking, and is currently pursuing U.S. Food and Drug Administration clearance, expected later this year.
Dr. Hak Seung Lee, Medical AI’s Chief Medical Officer—who accepted the award on the company’s behalf—said, “Artificial intelligence has the potential to fundamentally reshape how cardiovascular disease is detected and managed. By extracting deeper insights from standard ECG tests, we can help physicians spot signs of cardiovascular disease earlier and make more informed decisions in everyday clinical settings. We’re pleased ACC has recognized the value of our work with this award.”
The American College of Cardiology Annual Scientific Session is one of the world’s leading gatherings focused on cardiovascular medicine, bringing together cardiologists, researchers, and healthcare innovators from across the globe to share the latest advances in science, technology, and clinical practice.
About Medical AI
Medical AI is a digital health company focused on developing AI technologies that support clinicians in diagnosing and managing cardiovascular disease. The company specializes in AI-enabled ECG analysis solutions that leverage raw ECG data to enable earlier detection of multiple cardiovascular conditions and support more accurate clinical decision-making at scale across diverse care settings.
The company’s technology platform is supported by a growing body of clinical research, including over 70 SCI-indexed publications. Medical AI has obtained regulatory approvals in six countries, including CE marking, and is currently pursuing U.S. Food and Drug Administration clearance, expected in 2026.
Medical AI is headquartered in Seoul. For more information, visit www.medicalai.com.
CONTACT: U.S. Media Contact: Eliza Schleifstein ES Media +1 917 763-8106 eliza@schleifsteinpr.com
This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content.
Category: Top News, Daily News
SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.